MR Imaging of Pediatric Low-Grade Gliomas: Pretherapeutic Differentiation of BRAF V600E Mutation, BRAF Fusion, and Wild-Type Tumors in Patients without Neurofibromatosis-1

References

1. 1.↵
   1. Ostrom QT,
   2. Gittleman H,
   3. Truitt G, et al

   . CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Neuro Oncol 2018;20:iv1–86 doi:10.1093/neuonc/noy131 pmid:30445539

   CrossRefPubMed
2. 2.↵
   1. Krishnatry R,
   2. Zhukova N,
   3. Guerreiro Stucklin AS, et al

   . Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study. Cancer 2016;122:1261–69 doi:10.1002/cncr.29907 pmid:26970559

   CrossRefPubMed
3. 3.↵
   1. Armstrong GT,
   2. Conklin HM,
   3. Huang S, et al

   . Survival and long-term health and cognitive outcomes after low-grade glioma. Neuro Oncol 2011;13:223–34 doi:10.1093/neuonc/noq178 pmid:21177781

   CrossRefPubMed
4. 4.↵
   1. Stokland T,
   2. Liu J,
   3. Ironside JW, et al

   . A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neuro Oncol 2010;12:1257–68 doi:10.1093/neuonc/noq092 pmid:20861086

   CrossRefPubMed
5. 5.↵
   1. Bergthold G,
   2. Bandopadhayay P,
   3. Bi WL, et al

   . Pediatric low-grade gliomas: how modern biology reshapes the clinical field. Biochim Biophys Acta 2014;1845:294–307 doi:10.1016/j.bbcan.2014.02.004 pmid:24589977

   CrossRefPubMed
6. 6.↵
   1. Ryall S,
   2. Zapotocky M,
   3. Fukuoka K, et al

   . Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell 2020;37:569–83.e5 doi:10.1016/j.ccell.2020.03.011 pmid:32289278

   CrossRefPubMed
7. 7.↵
   1. Lassaletta A,
   2. Scheinemann K,
   3. Zelcer SM, et al

   . Phase II weekly vinblastine for chemotherapy-naïve children with progressive low-grade glioma: a Canadian pediatric brain tumor consortium study. J Clin Oncol 2016;34:3537–43 doi:10.1200/JCO.2016.68.1585 pmid:27573663

   Abstract/FREE Full Text
8. 8.↵
   1. Ater JL,
   2. Zhou T,
   3. Holmes E, et al

   . Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the children's oncology group. J Clin Oncol 2012;30:2641–47 doi:10.1200/JCO.2011.36.6054 pmid:22665535

   Abstract/FREE Full Text
9. 9.↵
   1. Ryall S,
   2. Tabori U,
   3. Hawkins C

   . Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun 2020;8:30 doi:10.1186/s40478-020-00902-z pmid:32164789

   CrossRefPubMed
10. 10.↵
    1. Fangusaro J,
    2. Onar-Thomas A,
    3. Poussaint TY, et al

    . Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 2019;20:1011–22 doi:10.1016/S1470-2045(19)30277-3 pmid:31151904

    CrossRefPubMed
11. 11.↵
    1. Hargrave DR,
    2. Bouffet E,
    3. Tabori U, et al

    . Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation–positive relapsed or refractory low-grade glioma: results from a phase I/IIa study. Clin Cancer Res 2019;25:7303–11 doi:10.1158/1078-0432.CCR-19-2177 pmid:31811016

    Abstract/FREE Full Text
12. 12.↵
    1. Nobre L,
    2. Zapotocky M,
    3. Ramaswamy V, et al

    . Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition. JCO Precis Oncol 2020561–71 doi:10.1200/PO.19.00298 pmid:32923898

    CrossRefPubMed
13. 13.↵
    1. Sievert AJ,
    2. Fisher MJ

    . Pediatric low-grade gliomas. J Child Neurol 2009;24:1397–1408 doi:10.1177/0883073809342005 pmid:19841428

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Mata-Mbemba D,
    2. Zapotocky M,
    3. Laughlin S, et al

    . MRI characteristics of primary tumors and metastatic lesions in molecular subgroups of pediatric medulloblastoma: asingle-center study. AJNR Am J Neuroradiol 2018;39:949–55 doi:10.3174/ajnr.A5578 pmid:29545246

    Abstract/FREE Full Text
15. 15.↵
    1. Patay Z,
    2. DeSain LA,
    3. Hwang SN, et al

    . MR imaging characteristics of wingless-type-subgroup pediatric medulloblastoma. AJNR Am J Neuroradiol 2015;36:2386–93 doi:10.3174/ajnr.A4495 pmid:26338912

    Abstract/FREE Full Text
16. 16.↵
    1. Perreault S,
    2. Ramaswamy V,
    3. Achrol AS, et al

    . MRI surrogates for molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol 2014;35:1263–69 doi:10.3174/ajnr.A3990 pmid:24831600

    Abstract/FREE Full Text
17. 17.↵
    1. Ishi Y,
    2. Yamaguchi S,
    3. Yoshida M, et al

    . Correlation between magnetic resonance imaging characteristics and BRAF alteration status in individuals with optic pathway/hypothalamic pilocytic astrocytomas. J Neuroradiol 2021;48:266–70 doi:10.1016/j.neurad.2019.05.006 pmid:31228537

    CrossRefPubMed
18. 18.↵
    1. Wagner MW,
    2. Hainc N,
    3. Khalvati F, et al

    . Radiomics of pediatric low-grade gliomas: Toward a pretherapeutic differentiation of BRAF- mutated and BRAF -fused tumors.AJNR Am J Neuroradiol Neuroradiol 2021;42:759–65 doi:10.3174/ajnr.A6998 pmid:33574103

    CrossRefPubMed
19. 19.↵
    1. Mistry M,
    2. Ryall S,
    3. Lassaletta A, et al

    . Lg-19 immunohistochemistry is highly sensitive and specific for the detection of BRAF v600e status in pediatric low-grade glioma. Neuro Oncol 2016;18:iii82.3–iii82 doi:10.1093/neuonc/now075.19

    CrossRef
20. 20.↵
    1. Kan P,
    2. Liu JK,
    3. Hedlund G, et al

    . The role of diffusion-weighted magnetic resonance imaging in pediatric brain tumors. Childs Nerv Syst 2006;22:1435–39 doi:10.1007/s00381-006-0229-x pmid:17021722

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Ho C,
    2. Mobley BC,
    3. Gordish-Dressman H, et al

    . A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation. Acta Neuropathol 2015;130:575–85 doi:10.1007/s00401-015-1467-3 pmid:26264609

    CrossRefPubMed
22. 22.↵
    1. Lassaletta A,
    2. Zapotocky M,
    3. Mistry M, et al

    . Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol 2017;35:2934–41 doi:10.1200/JCO.2016.71.8726 pmid:28727518

    CrossRefPubMed
23. 23.↵
    1. Horbinski C,
    2. Nikiforova MN,
    3. Hagenkord JM, et al

    . Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro Oncol 2012;14:777–89 doi:10.1093/neuonc/nos077 pmid:22492957

    CrossRefPubMed
24. 24.↵
    1. Behling F,
    2. Schittenhelm J

    . Oncogenic BRAF alterations and their role in brain tumors. Cancers 2019;11:794 doi:10.3390/cancers11060794 pmid:31181803

    CrossRefPubMed
25. 25.↵
    1. Hawkins C,
    2. Walker E,
    3. Mohamed N, et al

    . BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 2011;17:4790–98 doi:10.1158/1078-0432.CCR-11-0034 pmid:21610142

    Abstract/FREE Full Text
26. 26.↵
    1. Reitman ZJ,
    2. Paolella BR,
    3. Bergthold G, et al

    . Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. Nat Commun 2019;10:1–17 doi:10.1038/s41467-018-07882-8 pmid:30602773

    CrossRefPubMed
27. 27.↵
    1. Bartels U,
    2. Hawkins C,
    3. Jing M, et al

    . Vascularity and angiogenesis as predictors of growth in optic pathway/hypothalamic gliomas. J Neurosurg 2006;104:314–20 doi:10.3171/ped.2006.104.5.314 pmid:16848088

    CrossRefPubMedWeb of Science